Hospitals to receive additional remdesivir allocations

Jun 29, 2020 - 03:11 PM
Department of Health and Human Services (HHS) Seal

The Department of Health and Human Services today announced an agreement with drug maker Gilead Sciences to allow U.S. hospitals to purchase up to 500,000 treatment courses of remdesivir through September, which HHS and state health departments will allocate as they did the previous 120,000 treatment courses donated by the drug maker.

Under the agreement, hospitals will pay no more than the wholesale acquisition price for the drug, or $3,200 per treatment course, which AmerisourceBergen likely will ship to them every two weeks. The investigational drug has shown encouraging results treating certain COVID-19 patients in early clinical trials. HHS said the final donated treatment courses will ship today. To make future allocations of remdesivir, HHS will be asking hospitals and health systems to submit data every two weeks. The next data collection will be July 6.

AHA members will receive a Special Bulletin with more details.

Related News Articles

Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
OSHA extends comment period on proposal removing remaining COVID-19 emergency temporary standard requirements
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
CDC says COVID-19 cases growing or likely growing in 45 states 
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…